Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · IEX Real-Time Price · USD
2.360
-0.040 (-1.67%)
At close: Apr 25, 2024, 4:00 PM
2.310
-0.050 (-2.12%)
After-hours: Apr 25, 2024, 4:52 PM EDT
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.
Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 167 |
CEO | Sujal M. Patel |
Contact Details
Address: 2701 Eastlake Ave East Seattle, Washington 98102 United States | |
Phone | 206-333-2001 |
Website | nautilus.bio |
Stock Details
Ticker Symbol | NAUT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001808805 |
CUSIP Number | 63909J108 |
ISIN Number | US63909J1088 |
Employer ID | 98-1541723 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary and Director |
Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist and Director |
Anna Mowry | Chief Financial Officer and Treasurer |
Mary E. Godwin | Senior Vice President of Operations |
Matthew B. Murphy ESQ. | General Counsel |
Chris Blessington | Vice President of Corporate Marketing and Communications |
Gwen E. Weld | Chief People Officer |
Nick A. Nelson | Chief Business Officer and Senior Vice President of Business Development |
Dr. Subra Sankar Ph.D. | Senior Vice President of Product Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 6, 2024 | EFFECT | Notice of Effectiveness |
Mar 6, 2024 | 424B5 | Filing |
Mar 4, 2024 | UPLOAD | Filing |
Feb 28, 2024 | 8-K | Current Report |
Feb 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 28, 2024 | 10-K | Annual Report |
Feb 28, 2024 | 8-K | Current Report |
Dec 14, 2023 | 8-K | Current Report |
Nov 22, 2023 | 424B3 | Prospectus |